- Home
- PRQR vs TSHA Comparison
PRQR vs TSHA Comparison
Compare PRQR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- TSHA
- Stock Information
- Founded
- PRQR 2012
- TSHA 2019
- Country
- PRQR Netherlands
- TSHA United States
- Employees
- PRQR N/A
- TSHA N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- TSHA Health Care
- Exchange
- PRQR Nasdaq
- TSHA Nasdaq
- Market Cap
- PRQR 309.5M
- TSHA 334.1M
- IPO Year
- PRQR 2014
- TSHA 2020
- Fundamental
- Price
- PRQR $1.74
- TSHA $1.72
- Analyst Decision
- PRQR Strong Buy
- TSHA Strong Buy
- Analyst Count
- PRQR 6
- TSHA 8
- Target Price
- PRQR $8.17
- TSHA $6.63
- AVG Volume (30 Days)
- PRQR 381.0K
- TSHA 1.5M
- Earning Date
- PRQR 05-08-2025
- TSHA 02-26-2025
- Dividend Yield
- PRQR N/A
- TSHA N/A
- EPS Growth
- PRQR N/A
- TSHA N/A
- EPS
- PRQR N/A
- TSHA N/A
- Revenue
- PRQR $20,235,014.00
- TSHA $8,333,000.00
- Revenue This Year
- PRQR $210.18
- TSHA N/A
- Revenue Next Year
- PRQR $33.25
- TSHA N/A
- P/E Ratio
- PRQR N/A
- TSHA N/A
- Revenue Growth
- PRQR 306.68
- TSHA N/A
- 52 Week Low
- PRQR $1.61
- TSHA $1.19
- 52 Week High
- PRQR $4.62
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- PRQR 29.14
- TSHA 54.31
- Support Level
- PRQR $1.78
- TSHA $1.66
- Resistance Level
- PRQR $1.87
- TSHA $1.77
- Average True Range (ATR)
- PRQR 0.15
- TSHA 0.11
- MACD
- PRQR -0.05
- TSHA 0.01
- Stochastic Oscillator
- PRQR 2.34
- TSHA 47.62
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.